Proactive Investors - Run By Investors For Investors

Cosmos Holdings posts soaring revenue in 2018 as it launches new brand of food supplements

In 2018, the company's revenue jumped 23.6% to $37 million from $30 million in 2017
pharmaceutical vials
Cosmos Holdings specializes in acquiring, developing, and commercializing medicines

Cosmos Holdings Inc (OTCQB:COSM) saw its revenue soar in 2018 as it branched into the Nutraceutical market with the launch of its own brand of food supplements called Sky Premium Life.

In a statement, CEO Grigorios Siokas said the international pharmaceutical company will devote itself to building up its Sky Premium Life food supplement brand in 2019 as well as broadening its line of product offerings.

“Our focus in 2018 included increasing our core distribution business, formally launching our Sky Premium Life food supplement brand, expanding our direct to pharmacy reach, and vertically integrating into our supply chain,” Siokas said.

READ: Cosmos Holdings pays off all its convertible debt

In 2018, the company's revenue jumped 23.6% to $37 million from $30 million in 2017 while its gross profit climbed 23.1% to $2.4 million from $1.96 million in 2017.

Investors applauded the results, sending Cosmos shares up 10.37% to US$3.30 in afternoon trade on Tuesday.

In other milestones, the pharma company completed the acquisition of Cosmofarm Ltd, an Athens-based pharmaceutical wholesale company in December 2018, which features a robotic fulfillment center and an automated supply chain. It also recently paid off the remaining balance of its convertible notes, totaling $5.5 million.

READ: Cosmos posts 3Q profit and strong profit margins on booming drug sales and bolstered balance sheet

Cosmos Holdings specializes in acquiring, developing, and commercializing medicines. The Chicago-based company has offices and distribution centers in Thessaloniki, Greece and in the UK.


View full COSM profile View Profile

Cosmos Holdings Inc Timeline

Related Articles

October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use